J Gynecol Oncol | Volume 1, Issue 1 | Research Article | Open Access
Burcu Sanal Yılmaz1*, Pınar Karabağlı1, Uğur Arslan2, Özlem Ata3, Güler Yavaş4, Zeliha EsinÇelik1, Duygu Fındık2 and Çetin Çelik5
1Department of Pathology, Selçuk University Faculty of Medicine, Turkey
2Department of Microbiology, Selçuk University Faculty of Medicine, Turkey
3Department of Oncology, Selçuk University Faculty of Medicine, Turkey
4Department of Radiation Oncology, Selçuk University Faculty of Medicine, Turkey
5Department of Gynecological Oncology, Selçuk University Faculty of Medicine, Turkey
*Correspondance to: Burcu Sanal Yılmaz
Fulltext PDFIntroduction: Recent studies on Endometrial Carcinoma (EC) have focused on determining the clinicopathological factors that can be effectively considered in the prognosis, mortality risk, and targeted treatment of this disease. For this purpose, we investigated prognostic value of Golgi Phosphoprotein 3 (GOLPH3), which is associated with many different solid tumors, in EC. Although GOLPH3 has been shown to be a tumor-associated marker, the correlation between GOLPH3 expression, clinicopathological parameters, and clinical outcomes in EC has not been analyzed previously.
Materials and Methods: GOLPH3 expression was examined in 90 cases of EC and 11 cases of benign endometrial tissue. We investigated the association between GOLPH3 expression and clinicopathological features, chemotherapy, radiotherapy response, and prognosis using Polymerase Chain Reaction (PCR) and Immunohistochemistry (IHC). Results and
Discussion: GOLPH3 PCR protein levels were highly correlated with IHC expression in EC (p = 0.000). The GOLPH3 PCR value was also associated with distant metastasis and response to the treatment (p = 0.022 and p = 0.014, respectively). Neither IHC study nor PCR analysis showed statistically significant results for other clinicopathological parameters or survival. Moreover, no statistically significant difference was observed in histological grading and/or the malignant/benign distinction.
Conclusion: GOLPH3 overexpression in EC may be useful as a prognostic factor for predicting response to treatment and metastasis potential. However, the results must be evaluated in large patient groups to obtain detailed information.
Yılmaz BS, Karabağlı P, Arslan U, Ata Ö, Yavaş G, Çelik ZE, et al. Evaluation of Golgi Phosphoprotein 3 (GOLPH3) in Endometrial Carcinomas: A Molecular and Immunohistochemical Study. J Gynecol Oncol. 2018; 1(1): 1001.